Analysis and Comparison of Somatic Mutations in Paired Primary and Recurrent Epithelial Ovarian Cancer Samples

Yong-Man Kim1,4, Shin-Wha Lee1,4, Sung-Min Chun2,4, Dae-Yeon Kim1, Jong-Hyeok Kim1, Kyu-Rae Kim2, Young-Tak Kim1, Joo-Hyun Nam1, Paul van Hummelen3, Laura E. MacConaill3, William C. Hahn3, Se Jin Jang2,4,5

1 Department of Obstetrics & Gynecology, University of Ulsan, ASAN Medical Center, Seoul, Korea, 2 Department of Pathology, University of Ulsan, ASAN Medical Center, Seoul, Korea, 3 Center for Cancer Genome Discovery and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 4 ASAN Center for Cancer Genome Discovery, ASAN Medical Center, Seoul, Korea

Abstract

The TP53 mutations have been proved to be predominated in ovarian cancer in a study from The Cancer Genome Atlas (TCGA). However, the molecular characteristics of recurrent ovarian cancers following initial treatment have been poorly estimated. This study was to investigate the pattern of somatic point mutations in matched paired samples of primary and recurrent epithelial ovarian cancers, using the OncoMap mutation detection protocol. We have adapted a high-throughput genotyping platform to determine the mutation status of a large panel of known cancer genes. OncoMap v.4.4 was used to evaluate genomic DNA isolated from a set of 92 formalin-fixed, paraffin-embedded (FFPE) tumors, consisting of matched paired samples of initially diagnosed and recurrent tumors from 46 epithelial ovarian cancer (EOC) patients. Mutations were observed in 33.7% of the samples, with 29.3% of these samples having a single mutation and the remaining 4.3% having two or more mutations. Among the 41 genes analyzed, 35 mutations were found in four genes, namely, CDKN2A (2.2%), KRAS (6.5%), MLH1 (8.2%) and TP53 (20.7%). TP53 was the most frequently mutated gene, but there was no correlation between the presence of mutation in any gene and clinical prognosis. Furthermore, somatic mutations did not differ between primary and recurrent ovarian carcinomas. Every mutation present in recurrent samples was detected in the corresponding primary sample. In conclusion, these OncoMap data of Korean EOC samples provide that somatic mutations occurring in at least 96% of high-grade serous ovarian cancer and are known to be predictive of drug sensitivity or drug resistance [4]. Somatic mutations more than 30 oncogenes and tumor suppressor genes that have been implicated in ovarian onco genesis were detected in epithelial ovarian cancer (EOC) samples. Genetic changes drive altered signaling that induces proliferation; inhibits apoptosis; blocks anoikis; increases motility, adhesion, and invasion; and attracts stromal components, including mesenchymal stem cells and blood vessel endothelial cells [5]. This onco gene dependency provides the basis for therapies targeting oncogenes, such as the successful use of imatinib and erlotinib in cancers that harbor BCL-ABL and EGFR alterations, respectively. However, the mutational spectrum in ovarian cancer is surprisingly simple, as shown in a study from The Cancer Genome Atlas (TCGA). Mutations in TP53 predominated, occurring in at least 96% of high-grade serous ovarian cancer samples; furthermore, BRCA1 and BRCA2 were mutated in 22% of the tumors, owing to a combination of germline and somatic mutations. Seven other significantly mutated genes were identified, but only in 2–6% of high-grade serous ovarian cancer samples [6].

Citation: Kim Y-M, Lee S-W, Chun S-M, Kim D-Y, Kim J-H, et al. (2014) Analysis and Comparison of Somatic Mutations in Paired Primary and Recurrent Epithelial Ovarian Cancer Samples. PLoS ONE 9(6): e99451. doi:10.1371/journal.pone.0099451

Editor: Anthony W.J. Lo, The Chinese University of Hong Kong, Hong Kong

Received February 8, 2014; Accepted May 14, 2014; Published June 17, 2014

Copyright: © 2014 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by a grant of the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) (2011-0030105). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: jangsejin@amc.seoul.kr
We have adapted a high-throughput genotyping platform to determine the mutation status of a large panel of known cancer oncogenes in order to identify subsets of ovarian cancer patients who might benefit from targeted therapy related to their disease status [7–10]. This genotyping platform, called OncoMap, employs mass spectrometric-based genotyping technology (Sequenom) to identify 471 oncogenic mutations in 41 commonly mutated genes (Table S1). This study reports the type and frequency of somatic point mutations in paired primary and recurrent EOC samples using OncoMap.

Methods

Patients

The ASAN Center for Cancer Genome Discovery (CCGD), in collaboration with the Dana-Farber Cancer Institute (DFCI), has developed the OncoMap genotyping platform [8]. OncoMap v.4.4 was used to analyze a set of 92 formalin-fixed, paraffin-embedded (FFPE) EOC samples consisting of matched paired samples of initially diagnosed and recurrent tumors from 46 patients treated at the ASAN Medical Center, Korea, from January 2002 to December 2011. All patients had been treated with initial cytoreductive surgery followed by platinum-based chemotherapy and received a second cytoreductive surgery because of recurrent or metastatic disease. All tumor samples were obtained from FFPE tumor specimens based on an 80% cutoff for tumor sample purity. This study was approved by the ASAN Medical Center Institutional Review Board (AMC IRB), and we selected patients who had written the informed consent for using their archival tissues for genetic testing. All data was de-identified.

DNA Extraction

Review of all H&E slides was performed by a pathologist to confirm the tumor type, and to ensure that the sample was representative of the tumor and that normal surrounding tissues were not included. Genomic DNA was extracted from 10–20 6-μm-thick slides per FFPE block, depending on the tumor size. Purification of genomic DNA was performed using the QiAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. De-paraffinization with xylene and ethanol was carried out as follows. After incubation for 5 min with 1 ml xylene, the samples were centrifuged for 1 min at 12,000 rpm, and the supernatant was removed without disturbing the pellet. The samples were then washed with 1 ml of absolute ethanol in order to remove the remaining xylene, and the pellet was air-dried for 10 min to allow the residual ethanol to evaporate. The pellet was lysed by incubation with 0.2 mg of protease K overnight at 60 °C then subjected to column purification. Each genomic DNA sample was eluted in 50 μl of DNase- and Rnase-free water, quantified using the Quant-it™ PicoGreen dsDNA Assay kit (Invitrogen/Life Technologies, Grand Island, NY), and normalized to a 5 ng/μl concentration.

Genotyping Using OncoMap_v4.4-Core Panel

Profiling of somatic mutations for 41 critical genes related to tumor development was performed using OncoMap version 4.4-Core (OncoMap_v4.4C) under the Sequenom MassARRAY technology platform (Sequenom, San Diego, CA). OncoMap_v4.4C is a multiplex panel of 32 pools of genes that altogether span 471 unique mutation sites in 41 oncogenes and tumor suppressor genes (Table S1) that are known to be druggable targets. This OncoMap panel is an upgraded version of OncoMap_v1, which is described in published literature [7,8]. A total of 320 ng of purified genomic DNA was used as a template for 32 different pools of multiplex amplification using iPLEX chemistry (#10134–2; Sequenom, San Diego, CA), with 10 ng per reaction. An additional 50–80 ng of DNA was then used for homogenous Mass Extension (hME) validation of mutation candidates that were identified by the iPLEX reaction. Multiplex PCR amplification was performed on 10 ng of genomic DNA in a final volume of 5 μl in a 384-well plate with 0.5 U of HotStarTaq DNA Polymerase (Qiagen), 0.12 μl of each PCR primer, 500 μM of dNTP mix, and 3.5 mM MgCl2, using a DNA Engine Dyad Cycler (Bio-Rad, USA). Multiplex PCR was run with the following program: 95°C for 15 min; 45 cycles of 95°C for 20 sec, 56°C for 30 sec, and 72°C for 60 sec; then 72°C for 3 min. Residual deoxynucleotides in the PCR products were inactivated by incubation for 40 min at 37°C with 2 μl of shrimp alkaline phosphatase (SAP) from the iPLEX-Pro kit (#10142-2; Sequenom, San Diego, CA), followed by an additional incubation for 10 min at 85°C to inactivate the SAP. Next, single-base extension (SBE) was performed with an additional 2 μl of iPLEX Gold Chemistry mixture (0.1 μl of iPLEX termination mix, 1.2 μl of extension probe mix, and 0.0205 μl of iPLEX enzyme) as follows: 94°C for 30 sec; 40 cycles of 94°C for 5 sec and five internal cycles of (52°C for 5 sec and 90°C for 5 sec); and 72°C for 3 min. After SBE, 16 μl of DNase-free distilled water was added and desalting was performed by incubation for 25 minutes with 6 mg of cation exchange resin (Sequenom). Finally, 10 nl of the desalted product was spotted onto a 304-format SpectroCHIP II with the MassARRAY Nanodispenser (Sequenom). Mass determination was done with the MassARRAY Analyzer Compact MALDI-TOF mass spectrometer. Genotypes were called using a cluster analysis algorithm developed by the CCGD of DFCI, then reviewed manually by two independent researchers to eliminate any uncertain calls due to clustering artifacts. Sample quality was considered adequate for analysis if more than 80% of the attempted genotypes resulted in identifiable products. For validation of candidate mutations, specific hME genotyping was performed for whole samples. Validation pools for hME were designed using AssayDesigner software in the MassARRAY Typer package (v4.0). Proximal SNPs were filtered, and the specificity of PCR amplification and the subsequent primer extension reaction were confirmed with a maximum of six assays per pool. Multiplex PCR amplification and SAP treatment were conducted in the same manner as for the iPLEX reaction, except that 5 ng DNA was used for the multiplex PCR template. The hME reaction was performed with an additional 2 μl of hME master mix (0.2 μl of appropriate hME EXTEND mix, 1 μl of MassEXTEND primer mix, and 0.025 μl of ThermoSequence enzyme) as follows: 94°C for 2 min; 75 cycles of 94°C for 5 sec, 52°C for 5 sec, and 72°C for 5 sec; and 72°C for 5 min. The remaining steps, including addition of water, desalting, spotting, and analysis, were performed as for the iPLEX reaction. Only concordant calls from both the iPLEX and the hME analysis were considered to be validated mutations. All detected mutations were confirmed by standard, bidirectional Sanger sequencing.

Statistical Analysis

The survival analysis was performed using the Kaplan-Meier method and log rank test, and statistical significance was defined as p<0.05. SPSS v21.0 was used for all statistical analyses.
Results

In this study, 46 pairs of primary-recurrent EOC samples (i.e., 92 EOC samples of which 46 were from primary cancer sites and 46 were from matched paired recurrent sites) were analyzed. All patients had histologically confirmed EOC, of which papillary serous adenocarcinoma was most common (67.4%). All patients except one received adjuvant platinum-based chemotherapy between January 2002 and December 2011. The baseline characteristics of the patient population are summarized in Table 1.

Of the 92 FFPE samples tested, 35 mutations were identified and validated in 31 samples (33.7%). A single mutation was detected in 29.3% of the samples, and the remaining 4.3% had two or more mutations. The 35 mutations that were validated occurred in four genes, and 19 of these mutations were located in TP53 (Table 2). Mutations in genes TP53 (20.7%), MLH1 (8.7%), KRAS (6.5%), and CDKN2A (2.2%), with tumor suppressor gene TP53 the most commonly mutated gene in EOC (20.7% of the samples). This finding is in agreement with two recent reports that demonstrated that TP53 mutations are the most common somatic gene mutations in high-grade serous ovarian cancer [6,10]. However, there was no correlation between the presence of a mutation in the TP53 gene and clinical prognosis in total 46 patients. The median disease-free-survival (DFS) was 20.1 (range, 4.7–55.4) months in the TP53 mutation-negative group and 27.9 (range, 5.1–40.6) months in the TP53 mutation-positive group (P = 0.958). The median overall survival (OS) was 47.9 (15.8–177.4) months in the former and 55.0 (37.7–97.1) months in the latter group (P = 0.433) (Fig. 1). The survival analysis between TP53 wild type and TP53 mutant type obtained the same result when they only include 31 serous samples (Fig. 1). TP53 mutations and MLH1 mutations appeared in papillary serous adenocarcinoma, and otherwise KRAS mutations and CDKN2A mutations showed up mainly in mucinous adenocarcinoma (Table 3).

Next, the 46 pairs of primary and recurrent tumor samples were compared in order to evaluate the concordance rate of somatic

| Table 1. Clinicopathologic characteristics of patients. |
|--------------------------------------------------------|
|                                                        |
| **Age, median (range)**                                 |
| 48 (17–76)                                              |
| **FIGO stage**                                          |
| I 4 (8.7)                                               |
| II 2 (4.3)                                              |
| III 37 (80.4)                                           |
| IV 3 (6.5)                                              |
| **Histopathologic type**                                |
| Serous 31 (67.4)                                       |
| Mucinous 2 (4.3)                                       |
| Endometrioid 4 (8.7)                                   |
| Clear cell 2 (4.3)                                     |
| Transitional cell 1 (2.2)                             |
| Poorly differentiated 1 (2.2)                          |
| Mixed1 5 (10.9)                                        |
| **Residual mass**                                      |
| <1 cm 37 (80.4)                                        |
| ≥1 cm 9 (19.6)                                         |
| **Adjuvant chemotherapy**                              |
| Paclitaxel + Platinum 34 (73.9)                        |
| Cyclophosphamide + Platinum 6 (13.0)                  |
| Docetaxel + Platinum 5 (10.9)                         |
| Not done 1 (2.2)                                       |
| **Response to 1® treatment**                           |
| CR 37 (80.4)                                           |
| PR 4 (8.7)                                             |
| SD 3 (6.5)                                             |
| PD 1 (2.2)                                             |
| **DFS*, median (range)**                               |
| 22.2 (4.7–55.4)                                        |
| **Location of recurrent specimen**                     |
| Bowel 15 (32.6)                                        |
| Peritoneum 10 (21.7)                                  |
| Liver/Spleen 11 (23.9)                                |
| Ovary 5 (10.9)                                         |
| Lymph node 2 (4.3)                                     |
| other 3 (6.5)                                          |

1Serous adenocarcinoma and transitional cell carcinoma in 3 cases, serous adenocarcinoma and mucinous carcinoma in 1 case, and transitional cell carcinoma and poorly differentiated carcinoma in 1 case.

CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.

*DFS = disease-free-survival.

doi:10.1371/journal.pone.0099451.t001
mutations. Most patients showed the multiple metastases and the tested recurrent tumor samples were obtained from the local recurrence and distant metastasis (Table 3). Interestingly, any somatic mutations occurred in the only recurrent tumor had not detected in this OncoMap analysis of EOC (Table 4). An almost 100% concordance rate was observed when comparing mutations between primary and recurrent tumor pairs. The only one patient (case 12) showed a TP53 mutation in the primary sample, however, that was not detected in the recurrent sample. Furthermore, the frequency of mutation detection was similar between primary and recurrent tumor. In other words, somatic mutations were not affected by local recurrence or metastasis in EOC.

Discussion

OncoMap is an optimized mutation profiling platform developed to efficiently analyze mutations in known oncogenes and tumor suppressor genes, many of which are known to predict response or resistance to targeted therapies [8]. Our current version of OncoMap (v.4.4) interrogates 471 mutations in 41 genes that are relevant for cancer. The OncoMap platform can be used to analyze DNA derived from both fresh-frozen tissue and FFPE specimens. The sensitivity and specificity of OncoMap were 93.8% and 100%, respectively, in DNA derived from fresh-frozen tissue, and 89.3% and 99.4%, respectively, in FFPE-derived DNA [8]. When FFPE tissue is used, the sensitivity and specificity of OncoMap are comparable with results using fresh-frozen tissue. OncoMap has not been developed for a specific cancer type, so it has the limitation that contains many genes not to be relevant to a specific biology of each cancer. Nevertheless, the most remarkable advantage of OncoMap is that it enables the screening of hundreds of hotspot mutations from FFPE tissue at a reasonable cost [8]; therefore, this technology could make it easier for clinicians to screen for druggable mutations in diverse cancers. OncoMap has been already been reported as a reliable method for screening for somatic mutations in multiple solid tumor types [7,9–12].

An OncoMap study was performed in EOC to identify mutations that are druggable with novel biologic agents. Although EOC is not characterized by specific gene mutations (except for TP53, according to the TCGA data) [6], it is necessary to investigate the somatic mutations associated with differences in disease states. Overall, 31 (33.7%) of 92 FFPE tissues screened using OncoMap had somatic mutations. Of the EOC samples, 20.7% had TP53 mutations, and fewer samples harbored MLH1 (8.7%), KRAS (6.5%), or CDKN2A (2.2%) mutations.

TP53 is a tumor suppressor gene that encodes a protein mediating cell apoptosis, and loss-of-function mutation of TP53 is one of the most common features of human cancers [13]. From the first comprehensive mapping of the TP53 mutation rate in a homogeneous group of high-grade serous ovarian cancer patients, the overall TP53 dysfunction rate approached 100% of 123 patients. Pathogenic TP53 mutations were identified in 96.7% of these samples by sequencing exons 2–11 and intron-exon boundaries in tumor DNA [14]. Consistent with these published results, TP53 was mutated in 303 of 316 samples (95.9%) in the TCGA study [6]. The frequency of TP53 mutation was lower in our study (20.7%) compared to that reported in previous studies. Since OncoMap only investigates TP53 mutations at seven loci and does not detect deletion events, the lower rate of TP53 mutations observed in this study is in agreement with recent work from TCGA, as mentioned in another study performed using OncoMap (Fig. 2) [10]. This previous OncoMap study was performed on a set of 203 FFPE advanced staged high grade serous cancer of the ovary specimens in Dana-Farber Cancer Institute, using OncoMap v.3.0. We used an upgraded platform of OncoMap (v.4.4) including more gene and assays and investigated the mutation profile from only Korean women; however, the frequent somatic mutation of EOC was not distinctive comparing previous OncoMap study (Fig. 2). Numerous studies have evaluated the association between TP53 mutations in ovarian cancer and prognosis. Our data did not show differences in DFS or OS with respect to TP53 mutation status. Although there have been many reports that the presence of TP53 mutations is associated with prognosis in ovarian cancer, no association between TP53 mutation and progression-free or OS was found in the comprehensive mapping of TP53 mutation in the current study [14]. It is possible that the low number of patients with TP53 mutations may be insufficient to detect differences in prognosis.

Table 2. Frequency of mutations.

| Gene          | Validated mutations          | Total (N = 92) | % Primary (N = 46) | % Recurrent (N = 46) |
|--------------|----------------------------|---------------|------------------|---------------------|
| CDKN2A       | CDKN2A_H83Y.c.21961111G>A  | 2.2           | 2.2              | 2.2                 |
| KRAS         |                            | 6.5           | 6.5              | 6.5                 |
| KRAS_G12D_c25289551C>T | 4.3          | 2.2           | 2.2              | 2.2                 |
| KRAS_G12V_c25289551C>A  | 2.2           | 2.2           | 2.2              | 2.2                 |
| MLH1         | MLH1_V384D.c.37042244T>A  | 8.7           | 8.7              | 8.7                 |
| TP53         | TP53_R273H_c.7517845C>T    | 20.7          | 21.7             | 19.6                |
| TP53_R273C_c.7517846G>A  | 6.5           | 6.5           | 6.5              | 6.5                 |
| TP53_R248Q_c.7518263C>T  | 1.1           | 1.1           | 2.2              | 0.0                 |
| TP53_G245S_c.7518273C>T  | 4.3           | 4.3           | 4.3              | 4.3                 |
| TP53_R175H_c.7519131C>T  | 6.5           | 6.5           | 6.5              | 6.5                 |

doi:10.1371/journal.pone.0099451.t002

Mutations in Paired Epithelial Ovarian Cancer Samples
In this study, the second most commonly mutated gene in EOC was MLH1 (8.7%), which was not found to be mutated in the published OncoMap data in high-grade serous ovarian cancer. Germline mutations in mismatch repair genes, including MLH1, MSH2, and MSH6, have been identified in ovarian cancer patients with hereditary non-polyposis colorectal cancer (HNPCC) [15]. A study that included 1,893 women with EOC suggested that less than 1% of women with ovarian cancer harbor a germline mutation in the HNPCC genes, and pathogenic mutation carriers had an earlier mean age at diagnosis of ovarian cancer, with a greater likelihood of a non-serous histology, and a greater number of relatives with HNPCC-related cancers [15]. In a meta-analysis, somatic mutations in the MLH1 and MSH2 genes were found to be prevalent in colorectal cancer, in addition, a higher prevalence of somatic mutations in the MLH1 gene relative to the MSH2 gene was observed in the European group [16]. However, there are no reports on MLH1 somatic mutations in EOC. This is the first report detecting somatic mutations in MLH1 in sporadic EOC; therefore, there is no independent validation data available. It will be necessary to interrogate whether MLH1 somatic mutations are associated with specific ovarian cancer types.

KRAS mutations (6.5%) and CDKN2A mutations (2.2%) were also detected in this study. Mutations in the KRAS gene are one of the most frequent genetic abnormalities in ovarian cancer, and are more frequently present in carcinoma of a lower grade and International Federation of Gynecology and Obstetrics (FIGO) stage, and in lesions of a mucinous histotype [17]. KRAS mutation is associated with mucinous differentiation, because these mutations also accumulate in mucinous carcinomas of other organs [18,19]. Three patients had KRAS mutations, and that two of them had mucinous malignancies. Furthermore, it has recently been shown that pre-invasive ovarian mucinous tumors are characterized by cyclin-dependent kinase inhibitor 2A (CDKN2A) and Ras pathway aberrations [20]. Notably, the one patient with a CDKN2A mutation in our study also had a KRAS mutation. This study is the largest and highest-resolution analysis of mucinous benign and borderline tumors carried out to date and provides strong support for the hypothesis that these lesions are precursors of primary ovarian mucinous adenocarcinoma.

We investigated gene mutations in paired samples of initially diagnosed and recurrent tumors from 46 ovarian cancer patients. Many oncologists have been interested in intratumoral heterogeneity as well as the intertumoral heterogeneity between primary...
| Case | Age | FIGO Stage | Response to 1st treatment | Recurred site | Mutated gene | Sample site (P) | Cell type* (P) | Sample site (R) | Cell type* (R) |
|------|-----|------------|--------------------------|---------------|--------------|----------------|----------------|----------------|----------------|
| 01   | 46  | IIIc       | CR                       | Colon, LN, peritoneum | KRAS         | Ovary PSA      | Skin mass PSA | PSA            | PSA            |
| 02   | 36  | IIIc       | SD                       | Pericardium      | TP53         | Ovary PSA      | Pericardium PSA | PSA            | PSA            |
| 03   | 44  | IIIc       | CR                       | Liver            | MSH2         | Ovary PSA      | Ovary PSA      | Colon PSA      | PSA            |
| 04   | 42  | IIIc       | CR                       | Rectum, small bowel | TP53         | Ovary PSA      | Ovary PSA      | Colon PSA      | PSA            |
| 05   | 65  | IIIc       | CR                       | Paraaortic LN    | TP53         | Ovary PSA      | Paraaortic LN PSA | PSA            | PSA            |
| 06   | 48  | IIIc       | CR                       | Rectum, small bowel | TP53         | Ovary PSA      | Rectum PSA     | Paraaortic LN PSA | PSA            |
| 07   | 41  | IIIc       | CR                       | Peritoneum       | TP53         | Ovary PSA      | Peritoneum PSA | PSA            | PSA            |
| 08   | 56  | IIIc       | CR                       | Paraaortic LN    | TP53         | Ovary PSA      | Paraaortic LN PSA | PSA            | PSA            |
| 09   | 17  | IIIb       | CR                       | Ovary, chest wall, peritoneum | KRAS, CMV2A | Ovary PSA      | Ovary PSA      | MA             | MA             |
| 10   | 28  | IIc        | CR                       | Peritoneum       | TP53         | Ovary PSA      | Peritoneum PSA | MA             | MA             |
| 11   | 17  | IIIc       | CR                       | Paraaortic LN    | TP53         | Ovary PSA      | Paraaortic LN PSA | PSA            | PSA            |
| 12   | 60  | IIIc       | CR                       | Colon, small bowel | TP53         | Ovary PSA      | Colon PSA      | PSA            | PSA            |
| 13   | 57  | IIIc       | CR                       | Peritoneum       | TP53         | Ovary PSA      | Peritoneum PSA | PSA            | PSA            |
| 14   | 57  | IIIc       | CR                       | Peritoneum       | TP53         | Ovary PSA      | Peritoneum PSA | MA             | MA             |
| 15   | 57  | IIIc       | CR                       | Ovary, lymph node | TP53         | Ovary PSA      | Ovary PSA      | PSA            | PSA            |
| 16   | 57  | IIIc       | CR                       | Peritoneum       | TP53         | Ovary PSA      | Peritoneum PSA | PSA            | PSA            |

CR = complete remission; PR = partial response; SD = stable disease; PD = progressive disease.

`P` means the tumor sample from primary tumor and `R` means the tumor sample from recurrent tumor.

*PSA = papillary serous adenocarcinoma; MA = mucinous adenocarcinoma; EA = endometrioid adenocarcinoma; CCC = clear cell carcinoma; TCC = transitional cell carcinoma; PDC = poorly differentiated carcinoma.

LN = lymph node.

doi:10.1371/journal.pone.0099451.t003
Table 4. Concordance between primary and recurrent paired samples.

| Sample  | CDKN2A | KRAS | MLH1 | TP53 |
|---------|--------|------|------|------|
| P1      | 2.9%   |      |      |      |
| R1      | 23.0%  |      |      |      |
| P2      |        | 65.8%|      |      |
| R2      |        | 36.7%|      |      |
| P3      | 78.2%  |      |      |      |
| R3      | 70.0%  |      |      |      |
| P4      |        | 62.6%|      |      |
| R4      |        | 31.5%|      |      |
| P5      |        |      |      | 54.6%|
| R5      |        |      |      | 60.6%|
| P6      | 92.2%  |      |      |      |
| R6      | 93.9%  |      |      |      |
| P7      |        | 38.8%|      |      |
| R7      |        | 22.9%|      |      |
| P8      |        |      |      | 19.0%|
| R8      |        |      |      | 40.6%|
| P9      | 11.5%  |      |      |      |
| R9      | 6.4%   |      |      |      |
| P10     | 9%     | 60%  |      |      |
| R10     | 33%    | 21.9%|      |      |
| P11     | 57.2%  |      |      |      |
| R11     | 59.9%  |      |      |      |
| P12     |        | 76.0%|      |      |
| R12     |        | 0.0% |      |      |
| P13     |        |      |      | 78.9%|
| R13     |        |      |      | 70.3%|
| P14     | 99.5%  |      |      |      |
| R14     | 97.4%  |      |      |      |
| P15     | 57.5%  |      |      |      |
| R15     | 46.5%  |      |      |      |
| P16     | 60.0%  |      |      |      |
| R16     | 62.0%  |      |      |      |

*P means the tumor sample from primary tumor and R means the tumor sample from recurrent tumor. Percentage showed in table 4 means the ratio of mutant allele versus sum of wild and mutation for each position, that is to say the mutant allele frequency. doi:10.1371/journal.pone.0099451.t004
and recurrent tumor samples from the same patient. A large prospective study in breast cancer identified a switch in receptor status for ER in 10.2% of patients, for PR in 24.8%, and for HER2 in 2.9%; the switch in receptor status led to a change in the subsequent treatment plan for 17.5% of patients [21]. The authors, therefore, suggested that the management of relapsed breast cancer should include tissue sampling to identify switches in ER, PR, or HER2 status in locally recurrent or metastatic breast cancer, which may influence the planned treatment. Indeed, some reports in lung cancer have demonstrated discordant mutation patterns between primary and metastatic tumors and a heterogeneous distribution of epidermal growth factor receptor (EGFR) mutations in individual tumors [22–25]. However, heterogeneous mutations in KRAS and TP53 are scarce because these mutations are associated with the early pathogenesis of cancer [26]. In a report examining tumor samples from the Catalogue of Somatic Mutations in Cancer (COSMIC) database and the Aichi Cancer Center Cohort, no discordant mutation patterns were detected among 77 paired primary and metastatic site samples, or among 54 primary and recurrent tumor pairs [27]. The authors concluded that heterogeneous distribution of EGFR mutations is rare, but because mutant EGFR alleles are selectively amplified within tumors, samples analyzed by less sensitive detection methods may wrongly appear to be heterogeneous for EGFR mutations.

In ovarian cancer, some studies have shown discordant expression of genes or protein biomarkers in paired primary and relapsed ovarian cancer tissue samples, as measured by immunohistochemical analyses [28–30]. Recently, however, the opposite data has been reported that no new mutations arose from diagnosis to relapse after chemotherapy by exome sequencing of matched samples from one patient, suggesting that mutations already present in the primary tumor contributed to metastasis and chemotherapy resistance [31]. In our study, an almost 100% concordance rate was observed in paired primary and recurrent samples. Although one patient showed discordance, the TP53 mutation was detected in the primary sample, but not in the recurrent sample. Our findings suggest that these genes (TP53, MLH1, KRAS, and CDKN2A) are involved in early tumor development, as mentioned above.

This OncoMap analysis revealed that somatic mutations were rare in EOC. TP53 mutations were most common, consistent with published OncoMap and TCGA data, and somatic mutations in CDKN2A, KRAS, and MLH1 were also detected, although at much lower rates. Since there was no discordance between primary and recurrent samples, we could not find the specific somatic mutation associated to the tumor recurrence and distant metastasis in EOC, among well-known oncogenes and tumor suppressor genes. To understand the biology of tumor recurrence in EOC, more studies including epigenetic modifications or additional mutations in other genes are necessary. Furthermore, future studies will be necessary to correlate the presence of TP53 mutations with the biologic activity and clinical prognosis of the cancer. In addition, non-serous types of EOC should be analyzed, because molecular events in those cancers may provide an opportunity for treatments targeting specific mutations and pathways. Better functional genetics and disease stratification in ovarian cancer will make novel, targeted therapeutic targets and individualized treatments possible.

**Supporting Information**

Table S1 OncoMap 4.4C consists of 439 assays in 32 separate reactions designed to screen 471 mutations in 41 critical genes. (DOC)

**Author Contributions**

Conceived and designed the experiments: YMK SJJ. Performed the experiments: SWL SMC. Analyzed the data: YMK SWL. Organized and supervised the high-throughput mutation profiling: PH LM WCH SJJ. Contributed to the writing of the paper: DYK JHK KRK YTK JHN.

**References**

1. Boring CC, Squires TS, Tong T (1991) Cancer Statistics, 1991. CA Cancer J Clin 41: 19–36.
2. Liu J, Matulonis UA (2010) New advances in ovarian cancer. Oncology (Williston Park) 24: 721–729.
3. Boslom MA, Brady MF, McGuire WP, Harper PG, Alberts DS, et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419–1425.
4. Weinstein IB (2002) Cancer. Addiction to oncogenes—the Achilles heel of cancer. Science 297: 63–65.
5. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415–420.
6. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615.
7. Thomas RK, Baker AC, DeBiasi RM, Winckler W, Laffanboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347–351.
8. MacConaill LE, Campbell CD, Kelose SM, Bass AJ, Hatton C, et al. (2009) Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS One 4: e7887.
9. Maeng CH, Lee J, van Hummelen P, Park SH, Palecandolo E, et al. (2012) High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 7: e41655.
10. Matulonis UA, Hirsch M, Palecandolo E, Kim E, Liu J, et al. (2011) High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 6: e24433.
11. Choy E, Hornacek F, MacConaill L, Harmon D, Tariq Z, et al. (2012) High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 118: 2965–2974.
12. Lee J, van Hummelen P, Go C, Palecandolo E, Jung J, et al. (2012) High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 7: e38892.
13. Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223: 116–126.
14. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49–56.
15. Pal T, Aikhari MR, Sun P, Lee JH, Fulp J, et al. (2012) Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer 107: 1783–1790.
16. Zhang R, Qin W, Xu GL, Zeng FF, Li CX (2012) A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis 14: e80–89.
17. Auner V, Kriegsha¨user G, Tong D, Horvat R, Reinthaller A, et al. (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9: 111.
18. Endo K, Sasaki H, Yano M, Kobayashi Y, Yukie H, et al. (2006) Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 16: 533–541.
19. Karapetis CS, Khambata-Ford S, Jouker DJ, O’Callaghan CJ, Tu D, et al. (2008) Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1527–1535.
20. Hunter SM, Goringe KL, Christie M, Rowley SM, Bowtell DD, et al. (2012) Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res 18: 5267–5277.
21. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, et al. (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12: R92.
22. Taniguchi K, Okami J, Koizumi M, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99: 929–935.
23. Park S, Holness-Tisch AJ, Cho EY, Shin YM, Kim J, et al. (2009) Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 4: 809–815.
24. Goev GH, Chang YL, Hsu YG, Tsai MF, Wu CT, et al. (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small cell lung cancer. Ann Oncol 20: 696–702.
25. Nakano H, Seda H, Takasu M, Tomonaga N, Yamaguchi H, et al. (2008) Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 60: 136–140.
26. Li ZH, Zheng J, Weiss LM, Shibata D (1994) C-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Ann J Pathol 144: 303–309.
27. Yatabe Y, Matsuo K, Minoshima S (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29: 2972–2977.
28. Surowiak P, Materna V, Kapleuko I, Spacynski M, Dietel M, et al. (2006) Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 21: 713–720.
29. Penson RT, Oliver E, Skates SJ, Glynis T, Fuller AFJr, et al. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98–106.
30. Zajchowski DA, Karlan BY, Shawver LK (2012) Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11: 492–502.
31. Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, et al. (2013) Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 13: 146.